Voronoi, Inc.
Clinical trials sponsored by Voronoi, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing kinase inhibitors for cancer and inflammatory diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Will your breakfast ruin this cancer pill? new trial investigates Results expected Sep 2026 (estimated)
-
New pill targets Hard-to-Treat lung cancer mutations
Disease control Recruiting nowThis study tests an experimental oral drug called VRN110755 in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). The drug is designed to block cancer growth by targeting the EGFR protein and certain resistance mutations, including C797S. The tri…
Phase 1/2 • Sponsor: Voronoi, Inc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Will your breakfast ruin this cancer pill? new trial investigates
Knowledge-focused Recruiting nowThis early-stage trial in 24 healthy adults examines how food and a common stomach-acid reducer (a proton pump inhibitor) change the way the body absorbs a new drug called VRN101099, which is being developed for solid tumors. Researchers will measure drug levels in the blood and …
Phase 1 • Sponsor: Voronoi, Inc • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC